Clinical trial streating patients with severe COVID-19 with The C5 inhibitor Ululizumab-cwvz: upcoming
-
Last Update: 2020-05-29
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Alexion Pharmaceuticals said recently that it plans to launch a Phase III study of ravulizumab-cwvz for patients with COVID-19 acute respiratory distress syndromeUltomiris (ravulizumab-cwvz), a C5 supplement inhibitor, has been approved in the United States, Europe and Japan for the treatment of haemoglobinuria, which has been approved for atypical hemolytic uremic syndrome in the United StatesAlexion explained that publicly available preclinical data showed that inhibiting complements could reduce levels of cytokines and chemokines in animal models of viral pneumonia, which can significantly reduce inflammation of the lungsThe company also noted that patients using Another tonic inhibitor, Soliris, through "sympathetic use" have shown preliminary clinical evidence that tonic inhibition can improve coronavirus-mediated lung damagethe randomized study is expected to recruit about 270 patients in countries with high confirmed cases and will assess differences between Ultomiris and optimal supportive treatmentThe primary endpoint is the survival rate on the 29th day, and the secondary endpoint is the need for mechanical ventilation, the length of stay in the intensive care unit, and the safety
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
